Navigation Links
Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy
Date:2/3/2011

lthcare LLC is also developing other second-generation integrase inhibitors, including S/GSK1265744, currently in Phase II development.

About Shionogi & Co., LtdHeadquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company is the originator of innovative medicines which have been successfully delivered to millions of patients worldwide. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc. headquartered in Florham Park, NJ, please visit www.shionogi-inc.com.

About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com. Inquiries:UK Media inquiries:

Rebecca Hunt

(020) 8380 6275Claire Brough

(020) 8047 5502US Media inquiries:

Marc Meachem


'/>"/>

SOURCE Shionogi-ViiV Healthcare, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
4. Beckman Coulter to Present at the Thomas Weisel Healthcare Conference 2008
5. Beckman Coulter to Present at the Morgan Stanley Healthcare Unplugged Conference
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
8. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
9. Varian, Inc. to Present at Thomas Weisel Partners 2008 Healthcare Conference
10. Thermage, Inc. to Present at the 2008 Thomas Weisel Partners Healthcare Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the third quarter ended September 30,2007. ... for the three months ended September 30, 2007 ...
... MS, EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2007. "During the quarter, we continued to ... MBP8298, for the treatment of multiple,sclerosis," said Kevin ...
... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... Company appointed Joseph P. Slattery as a member ... committee. The appointment will be,effective as of November ...
Cached Biology Technology:Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9BioMS Medical announces third quarter 2007 results 2BioMS Medical announces third quarter 2007 results 3BioMS Medical announces third quarter 2007 results 4Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 2Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 3Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 4
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of serum long-chain omega-3 fatty acids may help reduce the ... Eastern Finland study published recently in Diabetes Care . ... oils. Type 2 diabetes is becoming increasingly widespread throughout ... factor, which means that diet and other lifestyle factors play ...
... launches today, investigating the social and political drivers and ... carbon dioxide emitter by volume, rather than focusing on ... worldwide we need to transform the way we power ... And nowhere is the approach to innovation across these ...
... been awarded to Cynthia Graber for her feature ,Electric ... regeneration?, published at MATTER. In ... journalist based in Massachusetts, investigates the work of Professor ... and Developmental Biology, to improve our understanding of the ...
Cached Biology News:Fish derived serum omega-3 fatty acids help reduce the risk of type 2 diabetes 2Story of human regeneration wins international physics journalism prize 2
... harvesting of cells • Blade design minimizes ... the growth surface • Designed for use ... wrapped • Sterilized by gamma radiation and ... a new product number, created to easily ...
... The MagneGST™ Protein Purification System ... method for the purification of glutathione-S-transferase ... particles (MagneGST™ Particles) are used to ... crude or cleared lysate using either ...
... versatile system that simultaneously harvests and washes ... into a solid filter supports for analysis ... counter. The FilterMate is ideal for the ... cell proliferation, receptor binding, nucleic acid degradation, ...
... A ready-to-use kit for a single fragment based screening project: ... each) , 96 shape-diverse mixtures of ... and dictionary files for structure refinement , ... of 4 are at ca. 50 mM. Supplied in 5 ...
Biology Products: